When called to lower prices, pharmaceutical giants instead have suggested that perhaps refunding SOME of the money paid for drugs that do not work as expected, back to insurers. Although not a new idea, the concept of pay-for-performance has recently grown as the industry seeks to defuse criticism. Read more here. (Source: Jared S Hopkins, Robert Langreth, James Paton, Bloomberg, 2/6/17)
You are here: / / Are Pay-for-Performance Deals a Good Compromise?